 Other companies have received 168 FDA Marketing Denial Orders for more than 992,000 flavored electronic nicotine delivery system products, and Refuse-to-File letters for approximately 4.5 million other products COSTA MESA, CA ACCESSWIRE September 13, 2021 Charlies Holdings, Inc. OTCQB:CHUC Charlies or the Company, an industry leader in both the premium, nicotine-based, e-cigarette space and the hemp-derived CBD wellness space, today announced Charlies Premarket Tobacco Product Applications PMTAs for the Companys best-selling e-liquids remain among the select minority of applications submitted to the U.S. Food and Drug Administration FDA that have not received Marketing Denial Orders or Refuse-to-File designations. Including product-specific scientific data, thorough perception studies, and detailed environmental assessments, Charlies PMTAs cost more than 5 million and are among the most comprehensive PMTAs in the entire industry. 